Objective::It remains unclear whether adjuvant chemoradiotherapy (CRT) improves survival outcome of pancreatic ductal adenocarcinoma (PDAC) patients after surgery. This study aimed to investigate the efficacy and safety of tegafur/gimeracil/oteracil (S-1)-based adjuvant concurrent chemoradiotherapy in resected PDAC patients with defined high-risk pathological features.Methods::We conducted a single-arm, prospective, and interventional study at Zhongshan Hospital Fudan University from December 2012 to December 2019 and the last follow-up was conducted in December 2021. This study was approved by the Ethics Committee of Zhongshan Hospital Fudan University on December 27, 2012 (approval No. B2012-139). Resected PDAC patients with high-risk pathological features, including positive resection margin, pathological T3-4N1-2M0 disease, peripancreatic fat invasion, microvascular invasion, and perineural invasion, were recruited. Primary endpoint was overall survival and secondary endpoints were disease-free survival, treatment toxicity, and 2-, 5-year survival rates.Results::A total of 54 patients were recruited. Mean age was 63.6 years old (±7.2). The distribution of T and N stages were 24.1% for T1, 46.3% for T2, 27.8% for T3, 1.9% for T4, 33.3% for N1, and 11.1% for N2. Seven patients had R1 resection. The median overall survival and disease-free survival were 27.1 and 13.7 months, respectively, while no fatal adverse events were recorded. Subgroup analyses showed differences in survival outcomes among patients with microvascular invasion, different N stages, and preoperative CA 19-9 levels. Further, a Cox proportional hazard model demonstrated associations of lymph node metastases, CA 19-9 level, and microvascular invasion with overall survival and disease-free survival.Conclusion::S-1 -based adjuvant CRT showed promising efficacy and manageable toxicity in resected PDAC patients with highrisk pathological features.

Adjuvant chemoradiotherapy;Pancreatic cancer;Pathology;S-1;Surgery

Wu Lili;Xu Yaolin;Zeng Zhaochong;Chen Yixing;Zhou Yuhong;Wang Dansong;Sun Jing;Lv Minzhi;Du Shisuo;Lou Wenhui

Department of Radiotherapy, Zhongshan Hospital Fudan University, Shanghai, China;Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China;Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China;Department of Biostatistics, Zhongshan Hospital Fudan University, Shanghai, China

胰腺病学杂志（英文）

[1]Wu Lili;Xu Yaolin;Zeng Zhaochong;Chen Yixing;Zhou Yuhong;Wang Dansong;Sun Jing;Lv Minzhi;Du Shisuo;Lou Wenhui-.Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study)[J].胰腺病学杂志（英文）,2022(01):18-26

tegafur,gimeracil,oteracil,B2012,Resected,4N1,peripancreatic,highrisk

Efficacy,safety,adjuvant,chemoradiotherapy,resected,ductal,adenocarcinoma,pathological,prospective,single,arm,interventional,study,Objective,It,remains,unclear,whether,CRT,improves,survival,PDAC,patients,after,surgery,This,aimed,investigate,efficacy,concurrent,defined,features,Methods,We,conducted,Zhongshan,Hospital,Fudan,University,from,December,last,follow,was,approved,by,Ethics,Committee,approval,No,including,positive,resection,margin,2M0,disease,invasion,microvascular,perineural,were,recruited,Primary,overall,secondary,endpoints,free,treatment,toxicity,rates,Results,total,Mean,years,old,distribution,stages,T4,N2,Seven,had,R1,median,months,respectively,while,fatal,adverse,events,recorded,Subgroup,analyses,showed,differences,outcomes,among,different,preoperative,CA,levels,Further,Cox,proportional,hazard,model,demonstrated,associations,lymph,node,metastases,Conclusion,promising,manageable,Adjuvant,Pancreatic,cancer,Pathology,Surgery

0.468357